Proteasome inhibitor therapy in multiple myeloma

Molecular Cancer Therapeutics

Volumn 4, Issue 4, 2005, Pages 686-692

  Chauhan, Dharminder ^a   Hideshima, Teru ^a   Mitsiades, Constantine ^a   Richardson, Paul ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CORTICOSTEROID; DEXAMETHASONE; DOXORUBICIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; IRINOTECAN; MELPHALAN; MG 115; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MITOXANTRONE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; RELVIMID; STRESS ACTIVATED PROTEIN KINASE; THALIDOMIDE; TRITERPENOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; CANCER INHIBITION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ENZYME REGULATION; ENZYME STRUCTURE; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTOPENIA; MALAISE; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; MYELOMA CELL; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PLEIOTROPY; PRIORITY JOURNAL; PROTEOMICS; SHORT SURVEY; SIDE EFFECT; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; NF-KAPPA B; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 18044395798     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0338     Document Type: Short Survey

References (71)

1. Anderson KC. Novel immunomodulatory therapies in the treatment of multiple myeloma. Oncology (Huntingt) 2004;18:988-90.
2. Anderson KC. Moving disease biology from the lab to the clinic. Cancer 2003;97:796-801.
3. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83-5.
4. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-26.
5. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82: 3712-20.
6. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 1996;87:1104-12.
7. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995;162:248-55.
8. Freund GG, Kulas DT, Mooney RA. Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol 1993;151:1811.
9. Podar K, Anderson KC. The pathophysiological role of VEGF in hematological malignancies: therapeutic implications. Blood 2005;105: 1383-95. Epub 2004 Oct 07.
10. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004;6:439-44.
11. Anderson KC. Bortezomib therapy for myeloma. Curr Hematol Rep 2004;3:65.
12. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61: 3071-6.
13. Chauhan D, Anderson KC. Mechanisms of cell death and survival in multiple myeloma (MM): therapeutic implications. Apoptosis 2003;8: 337-43.
14. Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci U S A 1998;95:2727-30.
15. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001;116:637-46.
16. Goldberg AL, Rock K. Not just research tools: proteasome inhibitors offer therapeutic promise. Nat Med 2002;8:338-40.
17. Ciechanover A. The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem Soc Trans 2003;31:474-81.
18. Elliott PJ, Pien CS, McCormack ID, Chapman ID, Adams J. Proteasome inhibition: a novel mechanism to combat asthma. J Allergy Clin Immunol 1999;104:1-7.
19. Lupas A, Koster AJ, Baumeister W. Structural features of 26S and 20S proteasomes. Enzyme Protein 1993;47:252-73.
20. Eytan E, Ganoth D, Armon T, Hershko A. ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. Proc Natl Acad Sci U S A 1989;86:7751-5.
21. Pickart CM. Back to the future with ubiquitin. Cell 2004;116: 181-90.
22. Lee JC, Peter ME. Regulation of apoptosis by ubiquitination. Immunol Rev 2003;193:39-47.
23. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003;15: 164-71.
24. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
25. Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002;16:433-43.
26. Yew PR, Kirschner MW. Proteolysis and DNA replication: the CDC34 requirement in the Xenopus egg cell cycle. Science 1997;277: 1672-6.
27. Verma R, Feldman RM, Deshaies RJ. SIC1 is ubiquitinated in vitro by a pathway that requires CDC4, CDC34, and cyclin/CDK activities. Mol Biol Cell 1997;8:1427-37.
28. Goebl MG, Yochem J, Jentsch S, McGrath JP, Varshavsky A, Byers B. The yeast cell cycle gene CDC34 encodes a ubiquitin-conjugating enzyme. Science 1988;241:1331-5.
29. Masdehors P, Omura S, Merle-Beral H, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999;105:752-7.
30. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. Faseb J 2000;14:65-77.
31. Kudo Y, Takata T, Ogawa I, et al. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000;6:916-23.
32. Bogner C, Schneller F, Hipp S, Ringshausen I, Paschal C, Decker T. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. Exp Hematol 2003;31:218-25.
33. Schenkein D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin Lymphoma 2002;3:49-55.
34. Stancovski I, Baltimore D. NF-κB activation: the IκB kinase revealed? Cell 1997;91:299-302.
35. Haefner B. NF-κB: arresting a major culprit in cancer. Drug Discov Today 2002;7:653-63.
36. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998;91:4624-31.
37. Alkalay I, Yaron A, Hatzubai A, et al. In vivo stimulation of IκB phosphorylation is not sufficient to activate NF-κB. Mol Cell Biol 1995; 15:1294-301.
38. Karin M, Yamamoto Y, Wang GM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
39. Feinman R, Koury J, Thames M, Barlogie B, Epstein J. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoids-induced apoptosis by Bcl-2. Blood 1999;93:3044-52.
40. Ogawa M, Nishiura T, Oritani K, et al. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res 2000;60:4262-9.
41. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44.
42. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;28:28.
43. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079-86.
44. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9.
45. Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003;63:6174-7.
46. Chauhan D, Li G, Hideshima T, et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem 2003;278:17593-6.
47. Chauhan D, Guilan L, Sattler M, et al. Superoxide-dependent and independent mitochondrial signaling during apoptosis in multiple myeloma (MM) cells. Oncogene. In Press 2003.
48. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Siol 2004;24:9695-704.
49. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003;278:33714-23.
50. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
51. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2: 927-37.
52. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-4.
53. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-jun/AP-1 signaling. Cancer Sci 2004;95:176-80.
54. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-35.
55. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001; 61:3535-40.
56. Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005;24:344-54.
57. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000;14:1276-83.
58. Williams SA, McConkey DJ. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 2003;63:7338-44.
59. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
60. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
61. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
62. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348: 2609-17.
63. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72.
64. Richardson PG, Sonneveld MS, Irwin D, et al. Bortezomib demonstrates superior efficacy to high-dose dexamethasone in relapsed multiple myeloma: final report of the APEX Study. San Deigo (CA): American Society of Hematology; 2004. Abstract.
65. Harousseau JL, Leleu X, Gressin R, Hulin C, Fuzibet JG, Troncy. Bortezomib (VELCADE®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM Phase II Study. San Deigo (CA): American Society of Hematology; 2004. Abstract.
66. Chauhan D, Li G, Podar K, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CODO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 2004; 103:3158-66.
67. Richardson PG, Hideshima T, Mitsiades C, Anderson K. Proteasome inhibition in hematologic malignancies. Ann Med 2004;36: 304-14.
68. Goy A, Gilles F. Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clin Lymphoma 2004;4:230-7.
69. Hideshima T, Podar K, Chauhan D, et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004;23:8766-76.
70. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002;7:9-16.
71. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56.